MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Cytokinetics Inc

Geschlossen

BrancheGesundheitswesen

40.38 0.22

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

39.4

Max

42

Schlüsselkennzahlen

By Trading Economics

Einkommen

11M

-150M

Verkäufe

16M

17M

EPS

-1.26

Gewinnspanne

-886.276

Angestellte

498

EBITDA

13M

-125M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+100.89% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

7. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-723M

5.1B

Vorheriger Eröffnungskurs

40.16

Vorheriger Schlusskurs

40.38

Nachrichtenstimmung

By Acuity

9%

91%

6 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

Cytokinetics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Juni 2024, 15:26 UTC

Akquisitionen, Fusionen, Übernahmen

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

5. Juni 2024, 14:14 UTC

Akquisitionen, Fusionen, Übernahmen

Cytokinetics: Board, Management Would Never Stand in Way of Value-Maximizing Transaction >CYTK

5. Juni 2024, 14:14 UTC

Akquisitionen, Fusionen, Übernahmen

Cytokinetics CEO: Board Would Have Supported Actionable Proposal in Best Interests of Shareholders >CYTK

5. Juni 2024, 14:14 UTC

Akquisitionen, Fusionen, Übernahmen

WSJ Reported in January That Novartis Backed Away From Pursuit of Cytokinetics >CYTK

5. Juni 2024, 14:14 UTC

Akquisitionen, Fusionen, Übernahmen

Cytokinetics CEO: Other Party Didn't Move Forward With Acquisition >CYTK

5. Juni 2024, 14:14 UTC

Akquisitionen, Fusionen, Übernahmen

Cytokinetics CEO: Board Was Supportive of Moving Forward on Deal on Terms Company Believed Would Be Mutually Acceptable >CYTK

5. Juni 2024, 14:14 UTC

Akquisitionen, Fusionen, Übernahmen

Cytokinetics CEO: Previously Held Good-Faith Talks With Another Party on Acquisition of Company >CYTK

Peer-Vergleich

Kursveränderung

Cytokinetics Inc Prognose

Kursziel

By TipRanks

100.89% Vorteil

12-Monats-Prognose

Durchschnitt 81.4 USD  100.89%

Hoch 120 USD

Tief 62 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cytokinetics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

18 ratings

17

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

37.46 / 42.705Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

6 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Cytokinetics Inc

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. It develops small molecule drug candidates primarily engineered to impact muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. The company has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.